A Phase 1 Study to Investigate the Safety and Pharmacokinetics of REGN2810 (Anti-PD-1) in Japanese Patients With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2019
At a glance
- Drugs Cemiplimab (Primary)
- Indications Cancer; Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Regeneron Pharmaceuticals
- 08 Jan 2019 Planned End Date changed from 5 Sep 2023 to 1 Aug 2023.
- 08 Jan 2019 Planned primary completion date changed from 5 Sep 2023 to 1 Aug 2023.
- 17 Sep 2018 Planned number of patients changed from 14 to 81.